CIK 0001178670
- Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770602661
- Phone
- +1 617-551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-10 | PYOTT DAVID E I Director | Option exercise | +3,780 | $71.99 | $272K | 5,362 |
| 2026-11-10 | PYOTT DAVID E I Director | Option exercise · Stock Option (Right to Buy) | −3,780 | 0 | ||
| 2026-11-10 | Sigal Charles Elliott Director | Purchase | +1,600 | $152.25 | $244K | 3,600 |
| 2026-11-09 | SCHULMAN AMY W Director | Purchase | +1,910 | $156.82 | $300K | 25,959 |
| 2026-10-02 | SUPRAN BRYAN EVP, CLO and Secretary | Sale | −1,758 | $226.88 | $399K | 12,807 |
| 2026-09-19 | Greenstreet Yvonne Chief Executive Officer | Grant or award | +107 | 95,802 | ||
| 2026-06-01 | PYOTT DAVID E I Director | Option exercise 10b5-1 | +3,830 | 5,412 | ||
| 2026-06-01 | PYOTT DAVID E I Director | Sale 10b5-1 | −921 | $297.71 | $274K | 4,491 |
| 2026-06-01 | PYOTT DAVID E I Director | Sale 10b5-1 | −1,175 | $298.91 | $351K | 3,316 |
| 2026-06-01 | PYOTT DAVID E I Director | Sale 10b5-1 | −1,222 | $299.87 | $366K | 2,094 |
| 2026-06-01 | PYOTT DAVID E I Director | Sale 10b5-1 | −495 | $300.72 | $149K | 1,599 |
| 2026-06-01 | PYOTT DAVID E I Director | Sale 10b5-1 | −17 | $302.65 | $5K | 1,582 |
| 2026-06-01 | PYOTT DAVID E I Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,830 | 0 | ||
| 2026-06-01 | Cravatt Benjamin Director | Grant or award · Stock Option (Right to Buy) | +4,393 | 4,393 | ||
| 2026-05-20 | Sigal Charles Elliott Director | Grant or award | +671 | 1,446 | ||
| 2026-05-20 | Sigal Charles Elliott Director | Grant or award · Stock Option (Right to Buy) | +1,441 | 1,441 | ||
| 2026-05-20 | SCHULMAN AMY W Director | Grant or award | +838 | 24,049 | ||
| 2026-05-20 | SCHULMAN AMY W Director | Grant or award · Stock Option (Right to Buy) | +1,802 | 1,802 | ||
| 2026-05-20 | Reitan Colleen F Director | Grant or award | +671 | 1,446 | ||
| 2026-05-20 | Reitan Colleen F Director | Grant or award · Stock Option (Right to Buy) | +1,441 | 1,441 |
Page 1 of 41 · 816 trades